secwatch / observer
8-K filed January 5, 2026, 6:59 PM ET ticker CLPT CIK 0001285550
debt confidence high sentiment neutral materiality 0.15

ClearPoint Neuro enters consent for Swedish subsidiary reorganization under note purchase agreement

ClearPoint Neuro, Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

ClearPoint Neuro, Inc. amended Consent to Note Purchase Agreement with CALW SA LLC (as Purchaser Agent) and TPC Investments III LP (affiliate of Oberland Capital Management LLC) valued at Consent to allow internal reorganization of Swedish subsidiary and qualify IRRAS AB as an Immaterial (effective 2025-12-29).

Action
amendment
Agreement
notes offering
Counterparty
CALW SA LLC (as Purchaser Agent) and TPC Investments III LP (affiliate of Oberland Capital Management LLC)
Value
Consent to allow internal reorganization of Swedish subsidiary and qualify IRRAS AB as an Immaterial
Effective
2025-12-29
Exact text from the filing
On December 29, 2025, the Company entered into a Consent (the “Consent”) with Purchaser Agent and the 2025 Investor providing for the Company to undertake the following actions no later than January 15, 2026: (i) an internal reorganization involving the Company’s Swedish subsidiary, IRRAS AB, including the transfer of all equity interests of IRRAS USA, Inc. owned by IRRAS AB to the Company or its direct, wholly owned U.S. subsidiary in exchange for a subordinated intercompany note, and (ii) other further actions so as to allow IRRAS AB to qualify as an “Immaterial Foreign Subsidiary” under the terms of the Note Purchase Agreement.
View on SEC.gov

324 material agreements filed in the last 30 days. Browse all material agreements →

ClearPoint Neuro, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-26-001581
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.